Revenue

CDW announces CFO Albert Miralles will retire in 2027, initiating a carefully planned succession amid strong financial performance and a dynamic IT market.

With its sixth straight quarter of double-digit growth, Extreme Networks leverages its AI platform and Wi-Fi 7 leadership to win major deals and reshape enterprise networking.

Nacon's path out of bankruptcy is now tied to its parent, Bigben Interactive. But the lifeline comes with a stark warning of 'significant dilution' for shareholders.

CDW's Q2 earnings beat expectations with a 10% sales jump, thanks to AI and cloud demand. But a dip in gross margins and restructuring costs spooked the market.

A quiet South Korean biotech is shaking up the drug delivery landscape. Alteogen's latest deal signals a major shift as Big Pharma races to make treatments better.

Valvoline's stellar Q3 results reveal a masterclass in corporate strategy, turning rising costs into record profits. But is this a sustainable model?

As J.M. Smucker prepares for a pivotal earnings call, a deeper look reveals a company balancing legacy brands with high-growth bets in a shifting market.

Shake Shack's Q2 results show impressive revenue growth and customer traffic, yet profits are shrinking. A deep dive reveals a company grappling with the high cost of expansion and inflation.

Acacia Research's Q2 results show a massive revenue jump from a patent deal, but a $31M write-down reveals the risks in its diversified strategy.

Eton Pharmaceuticals' new deal for ASN-001 is more than a pipeline buy; it's a calculated maneuver to capture the entire infantile hemangioma treatment space.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

Pyxus International's Q1 sales fell, but a forensic look reveals a firm mastering a flooded market, boosting margins and shoring up its financial foundations.

OCSL reports a slight income dip but showcases robust health with a stable NAV, a sharp drop in non-accruals, and consistent shareholder distributions.

Criteo's Q2 results reveal a company under severe pressure, with net income plummeting 49%. But behind the grim numbers, a high-stakes pivot to AI and a US redomiciliation is underway.

As Stella-Jones reports Q2 earnings, investors watch if robust demand for utility and rail products can offset residential market volatility and cost pressures.

As RLX Technology preps its Q2 report, all eyes are on whether its innovation and global strategy can overcome regulatory headwinds and define the next era.

As Everest Medicines preps its H1 2026 results, investors are watching for more than just profit, focusing on its pivot to a global innovation engine.

Zinzino's 20% sales jump masks a complex global story. While it conquers the Americas, its European home turf is faltering. What does this reveal?

The clock is ticking on a NOK 1.1B offer. We decode the strategic signals behind Brødrene A. & O. Johansen's bid to acquire Elektroimportøren.

With revenue doubling and overseas sales exploding, APR's Q2 results aren't just good—they're a blueprint for how beauty tech is conquering the West.